First patient dosed in Nacuity’s Phase III Usher syndrome RP trial
The double-masked, 24-month, randomised trial plans to recruit up to 80 adult patients.
News
Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting
First patient dosed in Enanta’s Phase IIb/III trial for RSV
Pfizer reports Phase II data for 25vPnC infant vaccine candidate
Granata Bio concludes screening in Phase III GRACE trial for IVF
Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
AstraZeneca and Oracle collaborate to test AI in clinical trial recruitment
Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint
